These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10646095)

  • 1. Economic aspects of vaccines and immunizations.
    Hinman AR
    C R Acad Sci III; 1999 Nov; 322(11):989-94. PubMed ID: 10646095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects for the use of new vaccines in developing countries: cost is not the only impediment.
    Hausdorff WP
    Vaccine; 1996 Sep; 14(13):1179-86. PubMed ID: 8961503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
    Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
    Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How important are airfreight rates and vaccine packaging in cost-saving efforts for the Expanded Programme on Immunization?
    Schreuder B; Arentsen H; Matosse M
    Bull World Health Organ; 1997; 75(4):315-21. PubMed ID: 9342890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.
    Wolfson LJ; Gasse F; Lee-Martin SP; Lydon P; Magan A; Tibouti A; Johns B; Hutubessy R; Salama P; Okwo-Bele JM
    Bull World Health Organ; 2008 Jan; 86(1):27-39. PubMed ID: 18235887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost analysis of producing vaccines in developing countries.
    Munira SL; Hendriks JT; Atmosukarto II; Friede MH; Carter LM; Butler JRG; Clements ACA
    Vaccine; 2019 Feb; 37(9):1245-1251. PubMed ID: 30651198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The global capacity for manufacturing vaccines. Prospects for competition and collaboration among producers in the next decade.
    Robbins A; Arita I
    Int J Technol Assess Health Care; 1994; 10(1):39-46. PubMed ID: 8157459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytics for vaccine economics and pricing: insights and observations.
    Robbins MJ; Jacobson SH
    Expert Rev Vaccines; 2015 Apr; 14(4):605-16. PubMed ID: 25435003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO expectation and industry goals.
    Vandersmissen W
    Vaccine; 2001 Feb; 19(13-14):1611-5. PubMed ID: 11166883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination strategies in developing countries.
    Poore P
    Vaccine; 1988 Oct; 6(5):393-8. PubMed ID: 3057759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund.
    Martin JF; Marshall J
    Vaccine; 2003 Jan; 21(7-8):587-92. PubMed ID: 12531322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obstacles to developing vaccines for the Third World.
    Robbins A; Freeman P
    Sci Am; 1988 Nov; 259(5):126-33. PubMed ID: 3212439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost of tetanus toxoid injection using a jet-injector (Imule) in collective immunization in Senegal: comparison with injection using a syringe and resterilizable needle].
    Schlumberger M; Châtelet IP; Lafarge H; Genêt A; Gaye AB; Monnereau A; Sanou C; Diawara L; Gueye Y; Lang J
    Sante; 1999; 9(5):319-26. PubMed ID: 10657777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.